여성 건강 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of women's health Market

The global women's health market is experiencing steady growth driven by the rising prevalence of women-centric diseases and increasing awareness regarding diagnosis, prevention, and treatment. According to the report, the global women's health market size was valued at USD 56.85 billion in 2025. The market is projected to be worth USD 60.44 billion in 2026 and reach USD 98.61 billion by 2034, exhibiting a CAGR of 6.31% during the forecast period. In 2025, North America dominated the market with a share of 51.4%, supported by high healthcare expenditure, strong adoption of women's health products, advanced healthcare infrastructure, and the rising prevalence of women-centric diseases.

Women's health includes healthcare products and treatments addressing conditions such as breast cancer, osteoporosis, menopause, infertility, contraception, and other reproductive and health-related conditions. Growing awareness programs, product launches, collaborations, and investments by pharmaceutical companies are contributing to market development.

Market Definition and Scope

The women's health market covers pharmaceutical products and healthcare solutions designed specifically to address women's medical requirements. Major application areas include contraceptives, osteoporosis, menopause, infertility, and other women's health conditions.

The market scope also includes distribution through hospital pharmacies, retail pharmacies, and online pharmacies. Increasing adoption of preventive healthcare, early diagnosis, reproductive health services, and specialized treatments is expanding the market across developed and emerging economies.

Market Dynamics

Drivers

The increasing prevalence of women-centric diseases and rising healthcare awareness is a major driver of market growth. Conditions such as breast cancer, osteoporosis, anemia, menopause, and infertility are increasing demand for specialized treatments. Greater awareness regarding early diagnosis and preventive healthcare is encouraging women to seek appropriate medical services.

Awareness campaigns and healthcare programs are also supporting adoption. The rising incidence of osteoporosis among women and the significant global burden of breast cancer are encouraging pharmaceutical companies and healthcare organizations to expand treatment and awareness initiatives.

Trends

A prominent market trend is the increasing number of strategic collaborations and acquisitions by market players. Companies are strengthening their women's healthcare portfolios through partnerships, acquisitions, and product commercialization. Bayer's acquisition of KaNDy Therapeutics strengthened its portfolio in menopause treatment, while other pharmaceutical companies have expanded their women's healthcare offerings through strategic transactions.

The growing emphasis on specialized reproductive health and innovative treatments is also influencing Women's Health Market Trends.

Restraints

The harmful effects and potential side effects associated with certain women's healthcare products can restrain market growth. Contraceptive pills may cause spotting, breast tenderness, nausea, and headaches. Some osteoporosis treatments may also cause adverse effects, while certain medicines may carry cardiovascular risks. Such concerns can influence treatment decisions and limit adoption of some products.

Impact of COVID-19

The COVID-19 pandemic negatively affected the women's health market during the early stages of the outbreak. Lockdowns, healthcare restrictions, postponed non-urgent treatments, and reduced hospital visits affected pharmaceutical sales. Bayer, for instance, reported an 8.8% decline in pharmaceutical sales, with its business affected by canceled and postponed treatments.

Changes in patient purchasing behavior also affected the market, as some patients preferred purchasing medicines rather than visiting hospitals because of concerns regarding coronavirus infection. However, demand for essential healthcare products and the gradual reopening of healthcare facilities supported market recovery.

Segmentation Analysis

By application, contraceptives dominate the market, accounting for a 34.2% share in 2025. Growth is supported by increasing awareness of reproductive health, demand for birth-control products, and product launches by pharmaceutical companies. The osteoporosis segment held the second-largest position, supported by the increasing prevalence of osteoporosis among women and growing healthcare expenditure.

By distribution channel, hospital pharmacies lead the market because many women's healthcare medicines require prescriptions and medical evaluation by trained professionals. Government investments in hospital infrastructure further support the segment. Meanwhile, online pharmacies are expected to experience rapid growth due to convenience, accessibility, and discounts.

Regional Insights

North America leads the global women's health market, reaching USD 18.00 billion in 2025. Strong healthcare expenditure, high adoption of women's health products, advanced infrastructure, and the prevalence of diseases such as breast cancer support regional dominance.

Europe is the second-largest region, supported by growing awareness of women's diseases and developed healthcare infrastructure. Asia Pacific is expected to record the highest growth rate, driven by increasing awareness, rising healthcare expenditure, and government initiatives in emerging economies such as China and India. Latin America and the Middle East & Africa represent comparatively smaller markets but offer opportunities because of significant untapped demand.

Competitive Landscape

The market is competitive, with major companies focusing on product innovation, collaborations, acquisitions, and distribution expansion. Key players include Bayer AG, Pfizer Inc., Amgen Inc., Novartis AG, Merck & Co., Inc., Eli Lilly and Company, LUPIN, AstraZeneca, and Agile Therapeutics.

Report Coverage

This report provides a comprehensive analysis of the global women's health market, covering market size for 2025, 2026, and 2034, growth drivers, trends, restraints, applications, distribution channels, regional insights, competitive landscape, and key industry developments. The report also highlights emerging Market Opportunities and product-development activities across major women's healthcare categories.

Conclusion

Growing from USD 56.85 billion in 2025 to USD 98.61 billion by 2034, the global women's health market is positioned for continued expansion. Rising prevalence of women-centric diseases, increasing healthcare awareness, strategic collaborations, product innovation, and expanding access to healthcare are expected to support market growth. North America maintains a leading position, while Asia Pacific offers significant growth opportunities. Continued development of specialized treatments, contraceptive products, menopause solutions, osteoporosis therapies, and accessible healthcare services will shape the market outlook through 2034.

Unit Value (USD Billion)

Segmentation Application; Distribution Channel and Geography

By Application

• Contraceptives
• Osteoporosis
• Menopause
• Infertility
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America
  • By Application
  • By Distribution Channel
  • By Country
• USA (By Application)
• Canada (By Application)
• Europe
  • By Application
  • By Distribution Channel
  • By Country/Sub-region
• The UK (By Application)
• Germany (By Application)
• France (By Application)
• Italy (By Application)
• Spain (By Application)
• Scandinavia (By Application)
• Rest of Europe (By Application)
• Asia Pacific
  • By Application
  • By Distribution Channel
  • By Country/Sub-region
• Japan (By Application)
• China (By Application)
• India (By Application)
• Australia (By Application)
• Southeast Asia (By Application)
• Rest of Asia Pacific (By Application)
• Latin America
  • By Application
  • By Distribution Channel
  • By Country/Sub-region
• Brazil (By Application)
• Mexico (By Application)
• Rest of Latin America (By Application)
• The Middle East & Africa
  • By Application
  • By Distribution Channel
  • By Country/Sub-region
• GCC (By Application)
• South Africa (By Application)
• Rest of the MEA (By Application)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence of Women Related Disorders, By Key Countries/Region
• 4.2. New Product Launches
• 4.3. Key Mergers, Acquisition, and Partnerships
• 4.4. Key Industry Trends
• 4.5. Impact of COVID-19 on Women's Health Market

5. Global Women's Health Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Contraceptives
  • 5.2.2. Osteoporosis
  • 5.2.3. Menopause
  • 5.2.4. Infertility
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital Pharmacies
  • 5.3.2. Retail Pharmacies
  • 5.3.3. Online Pharmacies
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Women's Health Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis - By Application
  • 6.2.1. Contraceptives
  • 6.2.2. Osteoporosis
  • 6.2.3. Menopause
  • 6.2.4. Infertility
  • 6.2.5. Others
• 6.3. Market Analysis - By Distribution Channel
  • 6.3.1. Hospital Pharmacies
  • 6.3.2. Retail Pharmacies
  • 6.3.3. Online Pharmacies
• 6.4. Market Analysis - By Country
  • 6.4.1. U.S.
    • 6.4.1.1. By Application
  • 6.4.2. Canada
    • 6.4.2.1. By Application

7. Europe Women's Health Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis - By Application
  • 7.2.1. Contraceptives
  • 7.2.2. Osteoporosis
  • 7.2.3. Menopause
  • 7.2.4. Infertility
  • 7.2.5. Others
• 7.3. Market Analysis - By Distribution Channel
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Retail Pharmacies
  • 7.3.3. Online Pharmacies
• 7.4. Market Analysis - By Country/Sub-region
  • 7.4.1. U.K.
    • 7.4.1.1. By Application
  • 7.4.2. Germany
    • 7.4.2.1. By Application
  • 7.4.3. France
    • 7.4.3.1. By Application
  • 7.4.4. Spain
    • 7.4.4.1. By Application
  • 7.4.5. Italy
    • 7.4.5.1. By Application
  • 7.4.6. Scandinavia
    • 7.4.6.1. By Application
  • 7.4.7. Rest of Europe
    • 7.4.7.1. By Application

8. Asia Pacific Women's Health Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis - By Application
  • 8.2.1. Contraceptives
  • 8.2.2. Osteoporosis
  • 8.2.3. Menopause
  • 8.2.4. Infertility
  • 8.2.5. Others
• 8.3. Market Analysis - By Distribution Channel
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Retail Pharmacies
  • 8.3.3. Online Pharmacies
• 8.4. Market Analysis - By Country/Sub-region
  • 8.4.1. Japan
    • 8.4.1.1. By Application
  • 8.4.2. China
    • 8.4.2.1. By Application
  • 8.4.3. India
    • 8.4.3.1. By Application
  • 8.4.4. Australia
    • 8.4.4.1. By Application
  • 8.4.5. Southeast Asia
    • 8.4.5.1. By Application
  • 8.4.6. Rest of Asia Pacific
    • 8.4.6.1. By Application

9. Latin America Women's Health Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis - By Application
  • 9.2.1. Contraceptives
  • 9.2.2. Osteoporosis
  • 9.2.3. Menopause
  • 9.2.4. Infertility
  • 9.2.5. Others
• 9.3. Market Analysis - By Distribution Channel
  • 9.3.1. Hospital Pharmacies
  • 9.3.2. Retail Pharmacies
  • 9.3.3. Online Pharmacies
• 9.4. Market Analysis - By Country/Sub-region
  • 9.4.1. Brazil
    • 9.4.1.1. By Application
  • 9.4.2. Mexico
    • 9.4.2.1. By Application
  • 9.4.3. Rest of Latin America
    • 9.4.3.1. By Application

10. Middle East & Africa Women's Health Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis - By Application
  • 10.2.1. Contraceptives
  • 10.2.2. Osteoporosis
  • 10.2.3. Menopause
  • 10.2.4. Infertility
  • 10.2.5. Others
• 10.3. Market Analysis - By Distribution Channel
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Retail Pharmacies
  • 10.3.3. Online Pharmacies
• 10.4. Market Analysis - By Country/Sub-region
  • 10.4.1. GCC Countries
    • 10.4.1.1. By Application
  • 10.4.2. South Africa
    • 10.4.2.1. By Application
  • 10.4.3. Rest of Middle East & Africa
    • 10.4.3.1. By Application

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Competition Dashboard
• 11.4. Comparative Analysis - Major Players
• 11.5. Company Profiles
  • 11.5.1. Bayer AG
    • 11.5.1.1. Overview,
    • 11.5.1.2. Products & Services,
    • 11.5.1.3. SWOT Analysis,
    • 11.5.1.4. Recent Developments,
    • 11.5.1.5. Strategies,
    • 11.5.1.6. Financials (based on availability)
  • 11.5.2. Pfizer Inc.
    • 11.5.2.1. Overview,
    • 11.5.2.2. Products & Services,
    • 11.5.2.3. SWOT Analysis,
    • 11.5.2.4. Recent Developments,
    • 11.5.2.5. Strategies,
    • 11.5.2.6. Financials (based on availability)
  • 11.5.3. Amgen Inc.
    • 11.5.3.1. Overview,
    • 11.5.3.2. Products & Services,
    • 11.5.3.3. SWOT Analysis,
    • 11.5.3.4. Recent Developments,
    • 11.5.3.5. Strategies,
    • 11.5.3.6. Financials (based on availability)
  • 11.5.4. Novartis AG
    • 11.5.4.1. Overview,
    • 11.5.4.2. Products & Services,
    • 11.5.4.3. SWOT Analysis,
    • 11.5.4.4. Recent Developments,
    • 11.5.4.5. Strategies,
    • 11.5.4.6. Financials (based on availability)
  • 11.5.5. Merck & Co., Inc.
    • 11.5.5.1. Overview,
    • 11.5.5.2. Products & Services,
    • 11.5.5.3. SWOT Analysis,
    • 11.5.5.4. Recent Developments,
    • 11.5.5.5. Strategies,
    • 11.5.5.6. Financials (based on availability)
  • 11.5.6. Eli Lilly and Company
    • 11.5.6.1. Overview,
    • 11.5.6.2. Products & Services,
    • 11.5.6.3. SWOT Analysis,
    • 11.5.6.4. Recent Developments,
    • 11.5.6.5. Strategies,
    • 11.5.6.6. Financials (based on availability)
  • 11.5.7. LUPIN
    • 11.5.7.1. Overview,
    • 11.5.7.2. Products & Services,
    • 11.5.7.3. SWOT Analysis,
    • 11.5.7.4. Recent Developments,
    • 11.5.7.5. Strategies,
    • 11.5.7.6. Financials (based on availability)
  • 11.5.8. AstraZeneca
    • 11.5.8.1. Overview,
    • 11.5.8.2. Products & Services,
    • 11.5.8.3. SWOT Analysis,
    • 11.5.8.4. Recent Developments,
    • 11.5.8.5. Strategies,
    • 11.5.8.6. Financials (based on availability)
  • 11.5.9. Other Players
    • 11.5.9.1. Overview,
    • 11.5.9.2. Products & Services,
    • 11.5.9.3. SWOT Analysis,
    • 11.5.9.4. Recent Developments,
    • 11.5.9.5. Strategies,
    • 11.5.9.6. Financials (based on availability)

12. Strategic Recommendations